Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN), a leading autoimmune testing solutions provider, has announced its participation in three major investor conferences. President and CEO John Aballi will present at the Canaccord Genuity MedTech Forum on November 21, 2024, at 3:00 p.m. EST in New York, the Evercore HEALTHCONx Conference on December 4, 2024, at 12:30 p.m. EST in Coral Gables, and will participate in a panel discussion titled 'Beyond Cancer' at the TD Cowen Diagnosing Tomorrow Conference on December 12, 2024, at 2:40 p.m. EST in New York. Management will also conduct one-on-one investor meetings at the first two events.

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor conferences:

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Company presentation by John Aballi, President and CEO on Thursday, November 21, 2024, at 3:00 p.m. EST at the Westin NY Grand Central Hotel. Management will also participate in one-on-one investor meetings.

Evercore HEALTHCONx Conference

Company presentation by John Aballi, President and CEO on Wednesday, December 4, 2024, at 12:30 p.m. EST at The Lowes Coral Gables Hotel in Coral Gables, FL. Management will also participate in one-on-one investor meetings.

TD Cowen Diagnosing Tomorrow Conference – Tools and Technologies for the Next Decade

John Aballi, President and CEO, with participate in a panel discussion titled: Beyond Cancer on Thursday, December 12, 2024, at 2:40 p.m. EST at One Vanderbilt, 20^th Floor, New York, NY.

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow @ExagenInc on X.

Exagen Inc.
Ryan Douglas
IR@exagen.com
760.560.1525

FAQ

What investor conferences will Exagen (XGN) attend in Q4 2024?

Exagen will attend three conferences: Canaccord Genuity MedTech Forum (Nov 21), Evercore HEALTHCONx Conference (Dec 4), and TD Cowen Diagnosing Tomorrow Conference (Dec 12).

When is Exagen's (XGN) presentation at the Canaccord Genuity MedTech Forum?

Exagen's CEO John Aballi will present at the Canaccord Genuity MedTech Forum on Thursday, November 21, 2024, at 3:00 p.m. EST at the Westin NY Grand Central Hotel.

What panel will Exagen (XGN) participate in at the TD Cowen Conference?

Exagen's CEO John Aballi will participate in a panel discussion titled 'Beyond Cancer' on December 12, 2024, at 2:40 p.m. EST at One Vanderbilt, New York.